23 Jul, 2026
According to Straits Research the global orthopedic biomaterials market was valued at $30.14 billion in 2025 and is anticipated to grow from $32.51 billion in 2026 to $59.51 billion by 2034, registering a CAGR of 7.85% during the forecast period 2026–2034.Biomaterials are used in numerous medical procedures, including orthopedics. Orthopedic biomaterials, created from organic or synthetic materials, help bones damaged by disease or trauma regain their structural integrity. Orthopedic biomaterials are employed in creating medical devices that the human body can use to replace or repair tissues such as ligaments, cartilage, bones, tendons, and more to perform biological functions.
Improvements in biomaterial technology raise the overall success rate of orthopedic surgery. Big players' high-quality products being released onto the market has a significant impact. These high-quality products and services support these players' efforts to grow their market share internationally. For instance, according to a report published by the American Joint Replacement Registry, the development of the registry and the identification of best practices led to a 50% decrease in revision rates of hip and knee implants in 2017. However, according to the FDA approval study, the success rate for implantation is 95.6%, the highest success rate in the US in 2016. The success rate of medical implants is a significant factor in demand growth. Therefore, improvements in surgical outcomes are expected to fuel the growth of the global orthopedic biomaterial market over the forecast period.
Businesses are eagerly introducing modern technologies. A wide variety of devices are on the market for different medical conditions. The focus of the players is on developing innovative products. For instance, Zimmer Biomet Holdings, Inc., a US-based healthcare solutions provider, received FDA 510(k) clearance in September 2019 for the Persona Revision Knee System for revision knee replacement procedures. It offers anatomical components that are custom-fit to a patient's anatomy. As the demand for implant procedures rises and medical implant technology develops quickly in developing countries, there will likely be more opportunities. As a result, the orthopedic biomaterial market will experience significant growth in overall volume and value.
Americas is the most significant shareholder in the global orthopedic biomaterial market and is expected to grow at a CAGR of 7.92% during the forecast period. The high prevalence of orthopedic diseases, the introduction of new products, and technological advancements in this field all contribute to this. Due to the region's ample supply of skilled laborers and the high demand for orthopedic biomaterial, the regional market is anticipated to expand. In addition, the demand for orthopedic biomaterials is expanding as the US population ages. According to the Administration for Community Living, the number of people 65 and older increased in the Americas over the past ten years, rising from 37.2 million in 2006 to 49.2 million in 2016. Therefore, the orthopedic biomaterial market in the Americas is anticipated to grow during the study period due to factors like a sizable patient pool with orthopedic conditions, a rapidly growing orthopedic biomaterial market, and an increasing geriatric population.
Europe is expected to grow at a CAGR of 7.35% during the forecast period. This is due to an increase in patients and the accessibility of products in the region. In addition, Germany, Austria, Luxembourg, Switzerland, Finland, and Belgium were among the countries in the region with the greatest number of hip and knee replacements carried out in 2017. The average number of hip and knee replacements per 100,000 people in the OECD is 182 and 135. Since 2000, hip and knee replacement surgeries have rapidly increased in most OECD countries. The average number of hip and knee replacements increased from 2007 to 2017 by 30% and 40%, respectively. The increase in patients undergoing knee replacement is anticipated to support the local market's growth.
sales@straitsresearch.com